Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-06-28
2011-06-28
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S094500, C514S002600, C514S006900
Reexamination Certificate
active
07968103
ABSTRACT:
The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
REFERENCES:
patent: 4473647 (1984-09-01), Carpenter et al.
patent: 4987237 (1991-01-01), Myers et al.
patent: 5543300 (1996-08-01), Inglot et al.
patent: 6670323 (2003-12-01), Looker et al.
patent: 2001/0034037 (2001-10-01), Patel et al.
patent: 2002/0065211 (2002-05-01), Jacobs et al.
patent: 101 03 211 (2002-07-01), None
patent: 0 405 315 (1991-01-01), None
patent: 0 472 467 (1992-02-01), None
patent: 0 477 050 (1992-03-01), None
patent: 1 316 315 (2003-06-01), None
patent: 04-187640 (1992-07-01), None
patent: 06-157333 (1994-06-01), None
patent: WO 87/06830 (1987-11-01), None
patent: WO 95/13829 (1995-05-01), None
patent: WO 95/23156 (1995-08-01), None
patent: WO 95/26507 (1995-10-01), None
patent: WO 97/12855 (1997-04-01), None
patent: WO 97/25061 (1997-07-01), None
patent: WO 98/33948 (1998-08-01), None
patent: WO 01/34648 (2001-05-01), None
patent: WO 01/51008 (2001-07-01), None
Anspach et al., “Endotoxin removal by affinity sorbents,” J. Biochem. Biophys. Methods 49, 2001, pp. 665-681.
Setlow et al., J. of Bacteriology vol. 89, No. 5, 1237-1243 (1965).
D'Agnillo, F. et al., “Synergistic Toxicity of Acellular Hemoglobin and Lipopolysaccharide in Cultured Endothelial Cells Under Oxidative Conditions,” Blood, 98:53B (2001) (Abstract).
Simsa, J. et al., “Changes in the Contents of Some Rat Serum Proteins Under Pathologic Conditions, Part 2 the Influence of Some Further Noxious Factors in Comparison with the Effect of Ionizing Radiation,”Radiobiologia Radiotherapia, 15:509-519 (1974).
Westerwoudt, R.J. et al., “The Growth Promoting Activity of Lipopolysaccharide, Dextran Sulfate, and Red Cell Lysate Added to Hy-Clone Calf Serum,”Cellular Immunology, 81:268-275 (1983).
Alexander, C. and Rietschel, E., “Bacterial lipopolysaccharides and innate immunity.”Journal of Endotoxin Research, vol. 7, No. 3, pp. 167-202 (2001).
Bacher, M. et al., “An essential regulatory role for macrophage migration inhibitory factor in T-cell activation,”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 7849-7854 (1996).
Bacher, M. et al., “Migration Inhibitory Factor Expression in Experimentally Induced Endotoxemia,”American Journal of Pathology, vol. 150, No. 1, pp. 235-246 (1997).
Bernhagen, J. et al., “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features,”J. Mol. Med, vol. 76, pp. 151-161 (1998).
Bertok, L., “Role of Bile in Detoxification of Lipopolysaccharide,”American Society of Microbiology—1980 (D. Schlesinger, edition), pp. 91-93 (1980).
Bernier, I. et al., “Ligand-binding studies with a 23 kDa protein purified from bovine brain cytosol,”Biochimica et Biophysica Acta, vol. 871, pp. 19-23 (1986).
Bertini, R. et al., “Thioredoxin, a Redox Enzyme Released in Infection and Inflammation, Is a Unique Chemoatractant for Neutrophils, Monocytes, and T Cells,”The Journal of Experimental Medicine, vol. 189, No. 11, pp. 1783-1789 (1999).
Brabetz, W. et al., “Bacterial Lipopolysaccharides: Chemical Constitution, Endotoxic Activity, and Biological Neutralization,”Symposium in Immunology, vol. VIII, pp. 89-121 (M. Eibl et al. edit), Springer Berlin, Heidelberg (1999).
Bradenburg, K. et al., “Confirmation of lipid a, the endotoxic center of bacterial lipopolysaccharide,”Journal of Endotoxin Research, vol. 3, pp. 173-178 (1996).
Calandra, T. et al., “The Macrophage Is an Important and Previously Unrecognized Source of Macrophage Migration Inhibitory Factor,”J. Exp. Med., vol. 179, pp. 1895-1902 (1994).
Carrillo, E.H. et al., “Free Hemoglobin Enhances Tumor Necrosis Factor-α Production in Isolated Human Monocytes,”The Journal of Trauma, vol. 52, No. 3, pp. 449-452 (2002).
David, S.A, “The Interaction of Lipid A and Lipopolysaccharide with Human Serum Albumin,”Endotoxin in Health and Disease, (H. Brade edit), pp. 413-422 (1999).
Dunn, D.L. et al., “Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. VI. Effects of stroma-free hemoglobin and red blood cell stroma on mortality and neutrophil function,”Surgery, vol. 93, No. 5, pp. 653-659 (1983).
Freudenberg, M.A. and Galanos, C., “Bacterial Lipopolysaccharides: Structure, Metabolism and Mechanisms of Action,”Intern. Rev. Immunol., vol. 6, pp. 207-221 (1990).
Gorczynski, R.M. et al., “A fetal sheep liver extract reverses age-related increments in spontaneous and induced cytokine production by indirect environmental effects,”Immunology Letters, vol. 60, pp. 157-164 (1998).
Gorczynski, R.M, et al., “An antibody specific for interleukin-6 reverses age-associated changes in spontaneous and induced cytokine production in mice,”Immunology, vol. 92, pp. 20-25 (1997).
Goto, S. et al., “Intradermal administration of lipopolysaccharide in treatment of human cancer,”Cancer Immunol. Immunotherapy, vol. 42, pp. 255-261 (1996).
Inagawa, H. et al., “Anti-tumor Effect of Lipopolysaccharide by Intradermal Administration as a Novel Drug Delivery System,”Anticancer Research, vol. 17, pp. 2153-2158 (1997).
Kaca, W. et al., “Hemoglobin, a Newly Recognized Lipopolysaccharide (LPS)-binding Protein That Enhances LPS Biological Activity,”The Journal of Biological Chemistry, Vo. 269, No. 40, pp. 25078- 25084 (1994).
Kaca, W. and Roth, R., “Activation of complement by human hemoglobin and by mixtures of hemoglobin and bacterial endotoxin,”Biochimica and Biophysica Acta, vol. 1245, pp. 49-56 (1995).
Katayama, Y. et al., “Scrutiny Of The Endotoxin-Like Substance in Human Placenta,”Japanese Journal of Medical Science&Biology, vol. 28, pp. 304-307 (1975).
Lotan, R., “Retinoids in cancer chemoprevention,”The FASEB Journal, vol. 10, pp. 1031-1039 (1996).
Luderitz, O. et al., “Fixation of P32-labeled lipopolysaccharides (endotoxin) fromEscherichia colito human erythrocytes,” (article in German, no abstract available), Biochem. Z., vol. 30, No. 1, pp. 34-46 (1958).
Metz, C.N. and Bucala, R., “MIF,”Academic Press, Cytokine Reference (J. Oppenheim et al., edition), pp. 703-716 (2001).
Miller, R.A., “The Aging Immune System: Primer and Prospectus,”Science, vol. 273, pp. 70-74 (1996).
Munford, R.S. and Hall, C.L., “Detoxification of Bacterial Lipopolysaccharides (Endotoxins) by a Human Neutrophil Enzyme,”Science, vol. 234, pp. 203-205 (1986).
Nabika, T. et al., “Synergistic effect of ubiquitin on lipopolysaccharide-induced TNF-α production in murine macrophage cell line RAW 264.7 cells,”Bi
Alexander Christian
Bessler Wolfgang
Gorczynski Reginald
Hartman Alfred
Hofmann Petra
Kam Chih-Min
Lee Wyan-Ching M.
Ropes & Gray LLP
Ruskin Barbara A.
LandOfFree
Compositions comprising fetal hemoglobin and bacterial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising fetal hemoglobin and bacterial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising fetal hemoglobin and bacterial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661151